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Abstract Recurrence was first recognised as a clinical
problem in 1989 with the advent of sumatriptan. The his-
tory of recurrence in early sumatriptan randomised clinical
trials is described. Recurrence has been ascribed to patient-
dependent factors but experience with ergot alkaloids
suggested that recurrence can also be treatment-dependent.
Possible mechanisms for recurrence are discussed.
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‘‘This may imply that novel sumatriptan-like drugs
with a more rapid or extensive absorption or a longer
plasma half-life may not result in higher initial
response rates or prevention of headache recurrence’’
[1]
Introduction
It is noteworthy that recurrence was not perceived as a
‘‘specific clinical problem’’ in migraine therapy before the
advent of sumatriptan in the large clinical trial programme
which resulted in its introduction into clinical use of the
drug [2]. For the migraine patients no recurrence is one of
the most important attribute of triptan therapy [3–5].
Attempts to avoid recurrence with triptans, either by
using a second dose of sumatriptan or by using triptans
with longer elimination half-lives, have largely been
unsuccessful. In order to avoid recurrence, its mechanism
should be better elucidated.
In the following, the history of recurrence in migraine
treatment from 1989 onwards will be recapitulated. In
addition, the question of whether recurrence is patient-
dependent will be examined, and possible mechanism of
recurrence will be discussed.
History of recurrence
Early on in 1989, during the open phase II studies, attention
was drawn to the clinical problem of recurrence. Thus, in
an open study on subcutaneous sumatriptan 2–3 mg, ten
patients in one Danish centre were given a questionnaire
concerning recurrence within 24 h of treatment in the clinic
by Dr. Iversen, Gentofte Hospital, Denmark [6]. Five out of
ten migraine patients experienced that the migraine head-
ache recurred within 24 h after successful treatment in the
first case and these recurrences occurred within the usual
duration of the migraine attack [6]. In the other centres,
there was no systemic follow-up after the patients left the
clinic, and only one recurrence was observed in 101
patients [6]. This clearly demonstrated that in order to
observe recurrence one had to look for it by administration
of a questionnaire about it.
In the first edition of the guidelines [7] on clinical drug
trials in migraine of the International Headache Society
from 1991 the proposed primary efficacy parameter was as
follows: Number of attacks resolved within 2 h. It was
recommended that ‘‘number of migraine attacks resolved
within 2 h, before any escape medication, should usually
be the primary parameter of efficacy. Whenever an attack
remits within 2 h, and relapses within 24 h, it is a treatment
failure by this criterion’’ [7]. In practice this parameter is
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roughly similar to the later in 2000 proposed ‘‘sustained
pain-free’’ parameter which is defined ‘‘as pain-free within
2 h with no use of escape medication or relapse within
48 h’’ [8]. This was later modified to 24 h in the Lancet
meta-analysis [9]. In the comments from 1991 [7] it was
noted that ‘‘if a drug is effectively quickly in bringing
resolution of the attack, but the attack relapses because of a
short duration of action of the drug (as has been observed
in patients with longlasting attacks), repeated intake of the
same drug can be optional; this requires a special study
design’’ [7]. Thus the committee members were aware of
the problem of recurrence most likely by personal experi-
ences from the then ongoing extensive sumatriptan trial
programme [2].
In the triptan development programmes, recurrence
has been defined as headache relief (a decrease in
headache from moderate or severe to mild or none) after
2 h and recurrence of moderate or severe headache
within 24 h.
In one of the first randomised clinical trials (RCTs) on
subcutaneous sumatriptan 6 mg in 1991 recurrence was not
mentioned [10]. It was concluded in this American RCT
‘‘that sumatriptan is an effective treatment for patients with
migraine. A significant reduction in headaches, clinical
disability, nausea, and photophobia occurs within minutes
of a subjections injection, with lasting effects for up to
24 h’’ [10]. However, the patients kept a diary for 48 h
after receiving treatment and this conclusion was reached
despite the fact that only 34% of the patients remained
completely pain free for 24 h [10]. Also in the large oral
dose-defining study from 1991 there was no mention of
recurrence and no mention of a follow-up after treatment
[11].
Even in 1992 it was noted in a paper [12] on CNS
adverse events of subcutaneous sumatriptan that these AEs
had a short-lasting time profile parallel to the kinetics of
the drug whereas’’ the pharmacodynamic effect with
respect to headache, however, last for about 24 h’’ [10]’’.
In contrast, a multiple-dose study of oral sumatriptan
from 1991 reported recurrence in 48% of sumatriptan-
treated patients [13]. Similarly, in an international RCT on
subcutaneous sumatriptan, 6 mg which was done at the
same time, it was observed that the migraine recurred in
38% of patients within 24 h after subcutaneous sumatriptan
6 mg [14] Thus even with the most effective way of
administering a triptan a considerable recurrence rate was
found [15, 16].
In the two comparative RCTs, published in 1991 and
1992, in which oral sumatriptan (recurrence in 41–42%)
was compared with ergotamine (30%), and aspirin plus
metoclopramide (33%) recurrence was evaluated [17, 18].
From this time on, recurrence was evaluated in almost all
RCTs with triptans [16, 19, 20].
From 2000 when IHS [6] recommended sustained pain-
free and after the meta-analysis of oral triptans from 2001
in the Lancet [9], most studies have reported on this effi-
cacy measure instead of headache recurrence. In the meta-
analysis [9, 21] a rather low sustained pain-free response
was found. Thus for sumatriptan 100 mg sustained pain
free 2-24 h was 20% and for rizatriptan 10 mg (25%),
eletriptan (25%) and almotriptan (27%) it was somewhat
higher [21]. Even so, with the best oral treatment at that
time less than one-third of patients had a sustained pain-
free response.
Whereas addition of a second dose of sumatriptan did
not prevent headache recurrence [22–24] the combination
of sumatriptan 85 mg and naproxen 500 mg resulted in
more patients (24%) being sustained pain-free than after
sumatriptan 85 mg (16%) [25].
Is recurrence attack- or patient-dependent?
The pros and cons of recurrence being attack- or patient
dependent versus treatment-dependent are summarised in
Table 1. First, a second dose of oral sumatriptan 100 mg
was tried as a preventive drug for recurrence [22–24].
Sumatriptan was given double-blindly 2–4 h after an open-
labelled first dose of either subcutaneous [22] or oral
sumatriptan [23, 24]. The second dose of sumatriptan did
not decrease the incidence of recurrence compared with
placebo [22, 23, 25]. This indicated that the incidence of
recurrence did not correlate with the pharmacokinetics of
sumatriptan. In contrast, sumatriptan was found effective in
the treatment of recurrence in four RCTs [16].
In two studies from 1996, Visser et al. [1, 26] investi-
gated the problem of recurrence. In one study in 366
migraine patients risk factors for recurrence were evalu-
ated. Headache recurrence occurred more frequently in
patients with more severe attacks and longer untreated
attack duration [25] In a second study, Visser et al. [1]
could find no correlation between the recurrence of
migraine and the pharmacokinetics parameters or the
pharmacodynamics parameters (effect on cranial arteries as
measured by ultrasound) of subcutaneous sumatriptan
studied outside attacks. They concluded that recurrence is
most likely patient-dependent [1] and that the results ‘‘may
imply that novel sumatriptan-like drugs with a more rapid
or extensive absorption or a longer plasma half-life may
not result in higher initial response rates or prevention of
headache recurrence’’ [1]. Multivariate logistic regression
analysis of the eletriptan trial programme identified pre-
dictors of headache recurrence [27]. These predictors were
age of [35 years, females and severe attacks at baseline
[27]. This indicates that the recurrence is mainly patient-
dependent.
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In 2003, Ge´raud et al. [28] found a correlation between
the half-lives and recurrence rates of oral triptans. How-
ever, the incidence of recurrence depends on female gen-
der, age of C35 years, and severe baseline characteristics
[27], as mentioned above, and these factors were not
included in the analysis [28] To illustrate, in two RCTs
with zolmitriptan the treated migraine headache was
moderate in 73–75% of patients [29, 30], whereas in one
RCT with rizatriptan the treated migraine headache was
severe in 55% of patients [31]. The recurrence rates in
these RCTs with different baseline severity should thus not
be compared. Comparison of recurrence rates or sustained
pain-free response should thus only be performed in direct
comparative RCTs in which randomisation ensures com-
parable baseline severity of migraine headache and the
other predictors for recurrence [27].
In the analysis of recurrence with oral triptans [28]
recurrence rates of 17% for frovatriptan 2.5 mg and 33%
for sumatriptan 100 mg were used. In contrast, in a direct
comparative RCT frovatriptan 2.5 mg (25% recurrence)
with a half-life of 26 h did not result in significantly fewer
recurrences than sumatriptan 100 mg (31% recurrence)
with a half-life of 2 h [32]. This indicates that even with a
huge difference in elimination t among two triptans there
is no difference in recurrence. The most likely explanation
for this is that low triptan levels, as illustrated in Fig. 1, do
not influence the risk for recurrence.
In summary, there are thus several pros for recurrence
being attack- or patient-dependent.
In contrast, the effect of ergot alkaloids, less recurrence
than a triptan in five out of six RCTs in which this
parameter was measured [16] speaks strongly against
recurrence being patient-dependent. Similarly, the combi-
nation of sumatriptan and naproxen [24] resulted in more
patients being sustained pain-free (24%) than after suma-
triptan (16%) indicating a treatment factor for recurrence.
Possible mechanism of recurrence in migraine
Some patients have migraine attacks which if untreated last
up to 72 h [33]. It is a clinical observation that if they are
treated with a triptan they risk multiple recurrences with
intake of triptans one to two times a day for several days.
This indicates that the migraine process continues despite
symptomatic relief by a drug. It has correspondingly been
shown with PET scan that even after successful treatment
Table 1 Is recurrence attack- or patient-dependent?
References Methods Result
Rapoport et al. [22], Ferrari
et al. [23], Scott et al. [24]
Administration of sumatriptan 100 mg or placebo as
a second dose after 2–4 h for the prevention of
recurrence
No effect of sumatriptan on the incidence of
recurrence compared with placebo
Visser et al. [26] Analysis of 366 migraine patients Recurrence more frequently with severe attacks and
long duration of untreated attacks
Visser et al. [1] Pharmacokinetic and pharmacodynamic evaluation
after subcutaneous sumatriptan in migraine
patients outside attacks
No differences between patients with recurrence and
non-recurrence patients
Dodick et al. [27] Multivariate logistic regression analysis identified
predictors of headache recurrence in the eletriptan
trial program
Predictors of recurrence were: [35 years old,
females, and severe attacks at baseline
Tfelt-Hansen [32] RCT of frovatriptan (t = 26 h) versus sumatriptan
(t = 2 h)
Frovatriptan (25% recurrence) was not different
from sumatriptan (31% recurrence)a
Saxena and Tfelt-Hansen
[16]
Comparative RCTs of a triptan versus ergot
alkaloids
In five out of six RCTs significant less recurrence
with ergot alkaloids than with a triptan
Brandes et al. [25] RCT of naproxen plus sumatriptan versus
sumatriptan
More sustained pain-free (24%) after naproxen plus
sumatriptan than after sumatriptan (15%)
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Fig. 1 Plasma concentration of a hypothetical triptan with a terminal
elimination half-life of 12 h. The hypothetical limiting concentration
for an effect in migraine is shown by the horizontal line. After 6 h the
drug has no longer any anti-migraine effect and can recur
J Headache Pain (2009) 10:311–315 313
123
with subcutaneous sumatriptan the brainstem activation
found during migraine attacks is persistent [34, 35]. The
brain stem activation has been termed the ‘‘migraine gen-
erator’’ [36]. Also the postdromes, the most common being
tiredness, observed in 68% of patients, indicate [37] that
a process is ongoing after the actual attack. Similarly,
adverse events such as sedation after triptans occur more
frequently after successful treatment indicating demasking
of symptoms of the migraine attack [38]. One theoretical
way to circumvent this problem is the using of triptan with
a very long half-life, e.g., frovatriptan with a t of 26 h
(Table 1). However, as suggested in Fig. 1 the terminal t
may theoretically not be relevant for recurrence.
Finally, pharmacodynamics may be more important than
pharmacokinetics for recurrence. Ergotamine has a kinetic
t of 2 h, but a pharmacodynamic t of 10 h [39] due to a
tight binding to the arterial receptor. Thus, in vitro the
constrictor effect of ergotamine on human temporal and
coronary arteries cannot be washed out [40–42].
In rat middle cerebral artery the contractions induced by
ergotamine and dihydroergotamine (DHE) were typically
slow in on and off set (about 30–60 min) [43]. The long
duration of ergot alkaloids should be investigated further in
an attempt to design drugs with less recurrence [43]. DHE
has a terminal t of 10 h but, is in my opinion, more likely
the tight binding to the receptor that is important [44].
The slow dissociation from the receptor on arteries of
DHE and ergotamine also explains the slow onset of action
of ergot alkaloids (Fig. 2). The ergot alkaloids’ behaviour,
slow onset of action, and long duration of action, fits best
with an effect on arteries [39] or veins [44, 45].
Conclusion
Recurrence appeared as a significant clinical problem in the
large trial programme of sumatriptan. So far, attempts to
avoid recurrence have not been successful. Recurrence is
most likely both patient-dependent, viz. severe and
long-lasting untreated attacks which increase the risk of
recurrence [26], and treatment-dependent, viz. the longer
pharmacodynamic effect of ergot alkaloids with resulting
less recurrence [16, 39]. Among the triptans there are only
minor, but sometimes statistically significant differences in
recurrence and sustained pain-free responses [8, 21]. The
ideal drug for migraine should have a quick onset of action
like triptans and a long duration of effect like ergot alka-
loids. This could theoretically, however, based on the
pharmacodynamic factors mention above, be a futile
endeavour.
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